Boeri miRNA signature of risk for lung cancer
miRNA expression analyses in plasma samples collected 1-2 years before the onset of disease, at the time of CT detection and in disease-free smokers enrolled in the screening trial, resulted in the generation of miRNA signatures with strong predictive, diagnostic, and prognostic potential (area under the ROC curve > or = 0.85). The signature of diagnosis of lung cancer is comprised of 16 ratios composed from 13 miRNAs: 21, 92a, 140-3p, 17, 106a, 140-5p, 660, 19b, 451, 30c, 15b, 28-3p, 486-5p. (from PMID:21300873)
No member markers defined for this panel.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
This miRNA signature was able to identify the presence of aggressive lung cancer not only in tumor, but also in normal lung tissues and in plasma samples of patients. Moreover, miRNAs deregulated in plasma samples collected before clinical appearance of disease were powerful molecular predictors of high-risk disease development.
No associated resources found.